NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
Actuate Therapeutics Inc.
Philogen S.p.A.
Istari Oncology, Inc.
Eli Lilly and Company
Orbus Therapeutics, Inc.
Isarna Therapeutics GmbH